MacroGenics, Inc.
NASDAQTotal Valuation
MacroGenics, Inc. carries a market capitalization of 279.68M, placing it among publicly traded companies globally. Its enterprise value stands at 293.65M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 279.68M |
| Enterprise Value | 293.65M |
Share Statistics
MacroGenics, Inc. currently has 63.56M shares outstanding.
| Shares Outstanding | 63.56M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | 2.17 |
| PB Ratio | N/A |
| P/TBV Ratio | N/A |
| P/FCF Ratio | -13.33 |
| P/OCF Ratio | -12.75 |
Enterprise Valuation
| EV / Sales | 2.18 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
MacroGenics, Inc. maintains a current ratio of 12.22, meaning it holds 12.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 293.59, indicating elevated leverage, while an interest coverage ratio of -1.74 demonstrates limited ability to service its debt obligations.
| Current Ratio | 12.22 |
| Quick Ratio | 11.28 |
| Debt / Equity | 293.59 |
| Debt / EBITDA | N/A |
| Interest Coverage | -1.74 |
Financial Efficiency
| Return on Equity (ROE) | -146.33 |
| Return on Assets (ROA) | -27.80 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | -51.08 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 6.74 |
Taxes
| Income Tax | -777,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
MacroGenics, Inc.'s stock has gained approximately 120% over the past 52 weeks. The 50-day moving average sits at 4.21, while the 200-day moving average is 3.01.
| Beta (5Y) | N/A |
| 52-Week Price Change | 120% |
| 50-Day Moving Average | 4.21 |
| 200-Day Moving Average | 3.01 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, MacroGenics, Inc. generated 134.84M in revenue and converted that into -34.11M in net income, yielding earnings per share of -0.54. EBITDA reached -21.72M, while operating income came in at -26.90M.
| Revenue | 134.84M |
| Gross Profit | 103.61M |
| Operating Income | -26.90M |
| Pretax Income | -34.88M |
| Net Income | -34.11M |
| EBITDA | -21.72M |
| EBIT | -26.90M |
| Earnings Per Share (EPS) | -0.54 |
Cash Flow
MacroGenics, Inc. produced -22.98M in operating cash flow over the past twelve months. After subtracting -1.01M in capital expenditures, free cash flow totaled -23.99M - equivalent to -0.38 per share.
| Operating Cash Flow | -22.98M |
| Capital Expenditures | -1.01M |
| Free Cash Flow | -23.99M |
| FCF Per Share | -0.38 |
Margins
MacroGenics, Inc. operates with a gross margin of 76.84, reflecting its pricing power and cost economics. The operating margin of -19.95 and net profit margin of -25.29 provide insight into operational efficiency.
| Gross Margin | 76.84 |
| Operating Margin | -19.95 |
| Pretax Margin | -25.87 |
| Profit Margin | -25.29 |
| EBITDA Margin | -16.11 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 0.05 |
| FCF Yield | -7.50 |
Scores
MacroGenics, Inc. posts an Altman Z-Score of -19.58, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -19.58 |